List of Excipients in API famotidine 10 mg
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing famotidine 10 mg
Detailed excipient profiles for famotidine 10 mg
Excipient focus: CARNAUBA WAX
famotidine 10 mg drug variants containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
famotidine 10 mg drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
famotidine 10 mg drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
famotidine 10 mg drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
famotidine 10 mg drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
famotidine 10 mg drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
famotidine 10 mg drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
famotidine 10 mg drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
famotidine 10 mg drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
famotidine 10 mg drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| MARKSANS PHARMA LIMITED | famotidine 10 mg | 25000-086 |
| >Company | >Ingredient | >NDC |
famotidine 10 mg drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch